Azhar Z. Abbasi

Azhar Z. Abbasi

Auto-generated profile, based on publicly available information

Azhar Z. Abbasi

Advanced Pharmaceutics and Drug Delivery Laboratory, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2010 in Nanoscale
Verified
Journal Article
Closed access
PDF file
Loretta L. del MercatoLoretta L. del Mercato
Loretta L. del Mercato
Pilar Rivera_GilPilar Rivera_Gil
Pilar Rivera_Gil
AAAzhar Z. Abbasi
Azhar Z. Abbasi
MOMarkus Ochs
Markus Ochs
CGCarolin Ganas
Carolin Ganas
WPWolfgang Parak
Wolfgang Parak
In this review we provide an overview of the recent progress in designing composite polymer capsules based on the Layer-by-Layer (LbL) technology demonstrated so far in material science, focusing on their potential applications in medicine, drug delivery and catalysis. The benefits and limits of current systems are discussed and the perspectives on emerging strategies for designing novel classes of therapeutic vehicles are highlighted.

13 June 2017 in Nanoscale
Verified
Journal Article
Closed access
PDF file
SRSamara R. Alves Rico
Samara R. Alves Rico
AAAzhar Z. Abbasi
Azhar Z. Abbasi
GRGeise Ribeiro
Geise Ribeiro
TATaksim Ahmed
Taksim Ahmed
XWXiao Yu Wu
Xiao Yu Wu
DSDenise de Oliveira Silva
Denise de Oliveira Silva
A unique class of diruthenium(II,III) metallodrugs containing non-steroidal anti-inflammatory drug (NSAID), Ru2(NSAID), have been reported to show anticancer activity in glioma models in vitro and in vivo. This work reports the encapsulation of the lead metallodrug of ibuprofen (HIbp), [Ru2(Ibp)4Cl] or RuIbp, and also of the new analogue of naproxen (HNpx), [Ru2(Npx)4Cl] or RuNpx, in novel intravenously (i.v.) injectable solid polymer–lipid nanoparticles (SPLNs). A rationally selected composition of lipids/polymers rendered nearly spherical Ru2(NSAID)-SPLNs with a mean size of 120 nm and zeta potential of about −20 mV. The Ru2(NSAID)-SPLNs are characterized by spectroscopic techniques and the composition in terms of ruthenium-drug species is analyzed by mass spectrometry. The metallodrug-loaded nanoparticles showed high drug loading (17–18%) with ∼100% drug loading efficiency, and good colloidal stability in serum at body temperature. Fluorescence-labeled SPLNs were taken up by the cancer cells in a time- and energy-dependent manner as analyzed by confocal microscopy and fluorescence spectrometry. The Ru2(NSAID)-SPLNs showed enhanced cytotoxicity (IC50 at 60–100 μmol L−1 ) in relation to the corresponding Ru2(NSAID) metallodrugs in breast (EMT6 and MDA-MB-231) and prostate (DU145) cancer cells in vitro. The cell viability of both metallodrug nanoformulations is also compared with those of the parent NSAIDs, HIbp and HNpx, and their corresponding NSAID-SPLNs. In vivo and ex vivo fluorescence imaging revealed good biodistribution and high tumor accumulation of fluorescence-labeled SPLNs following i.v. injection in an orthotopic breast tumor model. The enhanced anticancer activity of the metallodrug-loaded SPLNs in these cell lines can be associated with the advantages of the nanoformulations, assigned mainly to the stability of the colloidal nanoparticles suitable for i.v. injection and enhanced cellular uptake. The findings of this work encourage future in vivo efficacy studies to further exploit the potential of the novel Ru2(NSAID)-SPLN nanoformulations for clinical application.